Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDCC Regulatory News (DCC)

Share Price Information for DCC (DCC)

Share Price is delayed by 15 minutes
Get Live Data
5,975.00    -40.00 (-0.67%)
Bid:
5,990.00
Ask:
5,995.00
Spread: 5.00 (0.083%)
Market Cap: £5.10b
DCC Live PriceLast checked at - London Stock Exchange

Intraday DCC Share Chart

Form 38.5A (EPT/RI)-DCC plc

8 May 2026 11:29

RNS Number : 6358D
JPMorgan Securities Plc
08 May 2026
 

Ap34

 

FORM 38.5(a) (EPT/RI)

 

IRISH TAKEOVER PANEL

 

DEALING DISCLOSURE UNDER RULE 38.5(a) OF THE IRISHTAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022BY A CONNECTED EXEMPT PRINCIPAL TRADER WITHRECOGNISED INTERMEDIARY STATUS AND DEALING INA CLIENT-SERVING CAPACITY

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

J.P. Morgan Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

DCC plc

(c) Name of the party to the offer with which exempt principal trader is connected: (Note 1)

Corporate broker and financial adviser to DCC plc

(d) Date dealing undertaken:

07 May 2026

(e) In addition to the company in 1(b) above, is the exempt principal trader also making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER (Note 2)

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

Ap35

 

(a) Purchases and sales

 

 

Class of relevant security (Note 3)

Purchases/ sales

Totalnumber of securities

Highest price per unit paid/ received

Lowest price per unit paid/ received

€0.25 ordinary shares

Purchase

133,661

58.1500 GBP

57.4500 GBP

Sale

119,895

 

58.1304 GBP

 

57.4385 GBP

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description e.g. CFD

Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities (Note 4)

Price perunit (Note 5)

€0.25 ordinary shares

Equity SWAP

Decrease Long

 

 

 

 

 

 

 

 

 

 

 

 

Decrease Short

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Increase Long

 

 

 

Increase Short

 

 

 

 

 

 

 

Opening a long position

 

Opening a short position

 

 

 

22,031

 3

 57

 293

 1,078

 347

 651

 735

 85

 330

 1,290

 9,201

 

 4,482

 245

 8,187

 1,532

 1,968

 7,468

 639

 196

 9

 1,076

 383

 211

 157

 287

 182

 190

 

 7,082

 184

 850

 

 314

 9,413

 24

 1,017

 23

 1,325

 1,704

 

 6,673

 

 2,285

 132

 1,490

 2,766

57.5997 GBP

57.9633 GBP

57.6558 GBP

57.4558 GBP

78.5313 GBP

57.4526 GBP

57.5431 GBP

57.5195 GBP

57.6997 GBP

57.6422 GBP

57.7820 GBP

57.6092 GBP

 

57.4569 GBP

57.7335 GBP

57.4500 GBP

57.7713 GBP

57.7961 GBP

57.8917 GBP

58.0514 GBP

58.0710 GBP

57.8277 GBP

57.5642 GBP

57.6642 GBP

57.9126 GBP

57.7864 GBP

57.7855 GBP

57.5602 GBP

57.8477 GBP

 

57.4737 GBP

57.4385 GBP

57.4471 GBP

 

57.4509 GBP

57.4500 GBP

57.5665 GBP

57.4586 GBP

58.0322 GBP

57.5583 GBP

57.8723 GBP

 

57.4500 GBP

 

57.6691 GBP

57.6397 GBP

57.6598 GBP

57.6774 GBP

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates (Note 4)

Exercise price per unit

Type  e.g. American, European etc.

Expirydate

Option money paid/ received per unit

 

 

 

 

 

 

 

 

 

(ii) Exercise

 

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise priceper unit (Note 5)

 

 

 

 

 

 

(d) Other dealings (including transactions in respect of new securities)

 

Class of relevant security

Nature of dealing e.g. subscription, conversion, exercise

Details

Price per unit (if applicable) (Note 5)

 

 

 

 

 

Ap36

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

 

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 None

 

Date of disclosure:

08 May 2026

Contact name:

Hetvi Shah

Telephone number:

44 2034 936359

 

Public disclosures under Rule 38 of the Rules must be made to a Regulatory Information Service.

 

Ap37

 

NOTES ON FORM 38.5(a)

 

1. See the definition of "connected principal trader" in Rule 2.2 of Part A of the Rules.

 

2. See the definition of "dealing" in Rule 2.1 of Part A of the Rules.

 

3. See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.

 

4. See Rule 2.5(d) of Part A of the Rules.

 

5. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.

 

6. If details included in a disclosure under Rule 38 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.

 

For full details of disclosure requirements, see Rules 8 and 38 of the Rules. If in doubt, consult the Panel.

 

References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ITPSSMFSAEMSEEI
Date   Source Headline
30th May 20229:00 amRNSDirector/PDMR Shareholding
26th May 20225:41 pmRNSDirector/PDMR Shareholding
17th May 20227:00 amRNSDCC plc Investor Event Today - Leading with Energy
17th May 20227:00 amRNSResults for the year ended 31 March 2022
7th Apr 20227:00 amRNSDCC plc Upcoming Events
28th Feb 202210:44 amRNSTotal Voting Rights
15th Feb 20227:00 amRNSDCC Technology Presentation and Webcast
8th Feb 20227:00 amRNSBoard Changes
8th Feb 20227:00 amRNSInterim Management Statement
3rd Feb 202211:54 amRNSDCC Technology Presentation and Webcast
15th Dec 20217:00 amRNSDCC Management Presentation
15th Dec 20217:00 amRNSDCC plc acquires Almo Corporation
30th Nov 20214:31 pmRNSTotal Voting Rights
26th Nov 20217:15 amRNSDirector Declaration
15th Nov 20214:25 pmRNSDirector/PDMR Shareholding
11th Nov 20214:58 pmRNSDirector/PDMR Shareholding
11th Nov 202111:25 amRNSDirector/PDMR Shareholding
9th Nov 202110:01 amRNSUpdate on Timing of Interim Results Announcement
9th Nov 20217:00 amRNSBoard Changes
9th Nov 20217:00 amRNSResults for the six months ended 30 September 2021
28th Sep 20217:00 amRNSDCC Healthcare Event
14th Sep 20212:33 pmRNSDCC Healthcare Event
16th Jul 20212:17 pmRNSResult of AGM
16th Jul 20217:00 amRNSBoard Changes
16th Jul 20217:00 amRNSInterim Management Statement
13th Jul 20217:10 amRNS2021 Sustainability Report
7th Jul 20217:01 amRNSMr Cormac McCarthy
17th Jun 202112:34 pmRNS2021 Annual Report, Notice of AGM and Proxy Form
1st Jun 20217:00 amRNSTotal Voting Rights
27th May 20215:47 pmRNSDirector/PDMR Shareholding
20th May 20219:45 amRNSDirector/PDMR Shareholding
18th May 20217:00 amRNSAppointment of Chairman Designate & Board Renewal
18th May 20217:00 amRNSResults for the year ended 31 March 2021
23rd Apr 20217:14 amRNSDirector Declaration
1st Apr 20217:13 amRNSDirector Declaration
23rd Mar 20217:06 amRNSDirector Declaration
15th Mar 20217:00 amRNSDCC Healthcare acquires primary care supplier
11th Mar 20219:12 amRNSUpdate on the Migration to Euroclear Bank
26th Feb 202112:26 pmRNSTotal Voting Rights
18th Feb 20212:12 pmRNSDCC Consents to Migration of Ordinary Shares
11th Feb 20215:02 pmRNSDirector/PDMR Shareholding
4th Feb 20215:01 pmRNSDirector/PDMR Shareholding
4th Feb 20211:46 pmRNSResult of EGM
2nd Feb 20217:00 amRNSInterim Management Statement
26th Jan 20217:43 amRNSDirector Declaration
7th Jan 20214:55 pmRNSHolding in Company TR-1
7th Jan 20217:36 amRNSNotice of Extraordinary General Meeting
5th Jan 20217:00 amRNSDCC Significantly Expands Presence - US LPG market
27th Nov 20202:31 pmRNSTotal Voting Rights
18th Nov 202010:05 amRNSEnabling energy transition webcast

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.